Combined therapy of mixed dyslipidemia in patients with high
cardiovascular risk and changes in the lipid target values and
atherogenic index of plasma

J 2014

Combined therapy of mixed dyslipidemia in patients with high cardiovascular risk and changes in the lipid target values and atherogenic index of plasma

ROSOLOVA, Hana, Milada DOBIASOVA, Vladimír SOŠKA, Vladimir BLAHA, Richard CESKA et. al.

Základní údaje

Originální název

Combined therapy of mixed dyslipidemia in patients with high cardiovascular risk and changes in the lipid target values and atherogenic index of plasma

Autoři

ROSOLOVA, Hana (203 Česká republika), Milada DOBIASOVA (203 Česká republika), Vladimír SOŠKA (203 Česká republika, garant, domácí), Vladimir BLAHA (203 Česká republika), Richard CESKA (203 Česká republika), Barbora NUSSBAUMEROVA (203 Česká republika), Terezie PELIKANOVA (203 Česká republika) a Miroslav SOUČEK (203 Česká republika, domácí)

Vydání

Cor et Vasa, Brno, Česká kardiologická společnost, 2014, 0010-8650

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Kód RIV

RIV/00216224:14110/14:00075601

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.crvasa.2014.01.003

UT WoS

000409977800008

Klíčová slova anglicky

AIP = log[triglycerides/ HDL-cholesterol]); Atherogenic index of plasma; Combined lipid-modifying therapy; Mixed dyslipidemia

Štítky

EL OK

Příznaky

Recenzováno

Změněno: 27. 1. 2015 00:40, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Purpose: To evaluate the safety and efficacy of combined lipid-modifying agents (statin + fenofibrate) on plasma lipid profile including the atherogenic index of plasma (AIP = log [TG/HDL-C]) in patients at high and very high cardiovascular (CV) risk and mixed dyslipi-demia. Method: A total of 81 patients (53 males, 28 females; 60 ± 9.8 years) were included. Mixed dyslipidemia was defined as having 2 of the following 3 lipid abnormalities: LDL-cholesterol (C) >2.5 mmol/l, HDL-C <1.0 mmol/l in males and <1.3 mmol/l in females, triglycerides (TG) >1.7 mmol/l. Global CV risk was estimated according to the current European guidelines. Management with fenofibrate (160-267 mg) + atorvastatin (10-20 mg) or simvastatin (20- 40 mg) was indicated for 6 months. Males and females were stratified according to the AIP risk categories: AIP <0.11 (low risk), AIP >0.21 (high risk). Results: About 3/4 of high or very high CV risk patients with mixed dyslipidemia (n = 81) suffer from impaired glucose metabolism (44% had type 2 diabetes, 30% had impaired fasting glucose). Six-months combined therapy reduced LDL-C (by 29%) and TG (by 40%) signifi-cantly, but the increase of HDL-C (by 3%) was not significant. There were 47% of males and 57% of females who achieved the target LDL-C levels (<25 or <1.8 mmol/l) and 14% of males and 37% of females who received non-HDL-C <2.6 mmol/l at the end of the study. Also AIP was decreased significantly in majority of the patients (high risk AIP decreased from 87% to 47% of males and from 71% to 25% of females). Conclusion: The combined lipid-modifying therapy led to a significant improvement of the plasma lipid profile, particularly of LDL-C, TG, non-HDL-C and AIP. Atherogenic index of plasma seems to be a very useful marker of CV risk in high and very high CV risk patients with mixed dyslipidemia and glucose abnormalities. More intensive management is needed in those patients.

Citovat

ROSOLOVA, Hana, Milada DOBIASOVA, Vladimír SOŠKA, Vladimir BLAHA, Richard CESKA, Barbora NUSSBAUMEROVA, Terezie PELIKANOVA a Miroslav SOUČEK. Combined therapy of mixed dyslipidemia in patients with high cardiovascular risk and changes in the lipid target values and atherogenic index of plasma. Cor et Vasa. Brno: Česká kardiologická společnost, 2014, roč. 56, č. 2, s. "e133-e139", 7 s. ISSN 0010-8650. Dostupné z: https://dx.doi.org/10.1016/j.crvasa.2014.01.003.

@article{1184607,
   author = {Rosolova, Hana and Dobiasova, Milada and Soška, Vladimír and Blaha, Vladimir and Ceska, Richard and Nussbaumerova, Barbora and Pelikanova, Terezie and Souček, Miroslav},
   article_location = {Brno},
   article_number = {2},
   doi = {http://dx.doi.org/10.1016/j.crvasa.2014.01.003},
   keywords = {AIP = log[triglycerides/ HDL-cholesterol]); Atherogenic index of plasma; Combined lipid-modifying therapy; Mixed dyslipidemia},
   language = {eng},
   issn = {0010-8650},
   journal = {Cor et Vasa},
   title = {Combined therapy of mixed dyslipidemia in patients with high cardiovascular risk and changes in the lipid target values and atherogenic index of plasma},
   volume = {56},
   year = {2014}
}

TY  - JOUR
ID  - 1184607
AU  - Rosolova, Hana - Dobiasova, Milada - Soška, Vladimír - Blaha, Vladimir - Ceska, Richard - Nussbaumerova, Barbora - Pelikanova, Terezie - Souček, Miroslav
PY  - 2014
TI  - Combined therapy of mixed dyslipidemia in patients with high cardiovascular risk and changes in the lipid target values and atherogenic index of plasma
JF  - Cor et Vasa
VL  - 56
IS  - 2
SP  - "e133-e139"
EP  - "e133-e139"
PB  - Česká kardiologická společnost
SN  - 00108650
KW  - AIP = log[triglycerides/ HDL-cholesterol])
KW  - Atherogenic index of plasma
KW  - Combined lipid-modifying therapy
KW  - Mixed dyslipidemia
N2  - Purpose: To evaluate the safety and efficacy of combined lipid-modifying agents (statin + fenofibrate) on plasma lipid profile including the atherogenic index of plasma (AIP = log [TG/HDL-C]) in patients at high and very high cardiovascular (CV) risk and mixed dyslipi-demia. Method: A total of 81 patients (53 males, 28 females; 60 ± 9.8 years) were included. Mixed dyslipidemia was defined as having 2 of the following 3 lipid abnormalities: LDL-cholesterol (C) >2.5 mmol/l, HDL-C <1.0 mmol/l in males and <1.3 mmol/l in females, triglycerides (TG) >1.7 mmol/l. Global CV risk was estimated according to the current European guidelines. Management with fenofibrate (160-267 mg) + atorvastatin (10-20 mg) or simvastatin (20- 40 mg) was indicated for 6 months. Males and females were stratified according to the AIP risk categories: AIP <0.11 (low risk), AIP >0.21 (high risk). Results: About 3/4 of high or very high CV risk patients with mixed dyslipidemia (n = 81) suffer from impaired glucose metabolism (44% had type 2 diabetes, 30% had impaired fasting glucose). Six-months combined therapy reduced LDL-C (by 29%) and TG (by 40%) signifi-cantly, but the increase of HDL-C (by 3%) was not significant. There were 47% of males and 57% of females who achieved the target LDL-C levels (<25 or <1.8 mmol/l) and 14% of males and 37% of females who received non-HDL-C <2.6 mmol/l at the end of the study. Also AIP was decreased significantly in majority of the patients (high risk AIP decreased from 87% to 47% of males and from 71% to 25% of females). Conclusion: The combined lipid-modifying therapy led to a significant improvement of the plasma lipid profile, particularly of LDL-C, TG, non-HDL-C and AIP. Atherogenic index of plasma seems to be a very useful marker of CV risk in high and very high CV risk patients with mixed dyslipidemia and glucose abnormalities. More intensive management is needed in those patients.
ER  -

ROSOLOVA, Hana, Milada DOBIASOVA, Vladimír SOŠKA, Vladimir BLAHA, Richard CESKA, Barbora NUSSBAUMEROVA, Terezie PELIKANOVA a Miroslav SOUČEK. Combined therapy of mixed dyslipidemia in patients with high cardiovascular risk and changes in the lipid target values and atherogenic index of plasma. \textit{Cor et Vasa}. Brno: Česká kardiologická společnost, 2014, roč.~56, č.~2, s.~''e133-e139'', 7 s. ISSN~0010-8650. Dostupné z: https://dx.doi.org/10.1016/j.crvasa.2014.01.003.

Podrobný výpis o publikaci